Welcome to the 25th case of the Skeleton Key Group, a team of 50-odd nephrology fellows who work together to build a monthly education package for the Renal Fellow Network. These are actual cases (without patient identifying information)…
Drug related adverse events may not be uncovered until new therapies have been on the market for many years and used among a wider patient population than in the initial clinical trials. Downing and colleagues summarized that, during…
The use of checkpoint inhibitors (CPIs) has revolutionized the approach to therapy in patients with aggressive hematological and metastatic solid malignancies. These novel immunotherapies have increased overall survival for our patients with an improved overall side effect profile…
